Fred Hutchinson
Women more likely to experience severe toxicity from cancer treatment
Women receiving cancer treatment in clinical trials exhibited higher risk for severe symptomatic and hematologic adverse events than their male counterparts, according to a study.
Breast cancer specialist appointed senior VP of clinical research at Fred Hutch
Sara A. Hurvitz, MD, has been appointed senior vice president of the clinical research division at Fred Hutchinson Cancer Center.
Seattle Children’s pauses trial of CAR-T for leukemia after patient death
Seattle Children’s Hospital has paused the phase 1 PLAT-08 trial of SC-DARIC33 after one patient treated with the investigational chimeric antigen receptor T-cell therapy died.
Novel leukemia treatment signals ‘new era in CAR T-cell therapy’
An investigational chimeric antigen receptor T-cell therapy demonstrated successful expansion and antitumor targeting among younger patients with advanced acute myeloid leukemia, results of the phase 1 PLAT-08 trial showed.
Researchers use CAR T-cell therapy to pursue new prostate cancer target
An immunotherapy regimen featuring a novel chimeric antigen receptor T-cell therapy demonstrated antitumor activity against metastatic prostate cancer models, study results published in Nature Communications showed.
Review highlights major advances, continuing challenges in chronic lymphocytic leukemia
The availability of highly effective targeted agents has changed the treatment landscape for chronic lymphocytic leukemia, but key questions about optimal strategies remain, according to a review published in JAMA.
Peer coaching increased genetic testing uptake in community oncology setting
Community oncologists who received peer coaching from cancer genetics experts more frequently ordered genetic testing for their patients, according to study results.
Cancer vaccine research may have reached ‘tipping point’
The concept of cancer vaccination has generated excitement in the scientific community for decades.
Iomab-B may increase transplant access, improve outcomes in relapsed/refractory AML
Targeted conditioning with iodine (131I) apamistamab enabled older patients with relapsed or refractory acute myeloid leukemia to undergo allogeneic hematopoietic stem cell transplantation, according to results of the phase 3 SIERRA trial.
‘Exciting’ research spotlights CAR-T’s evolving role in blood cancer treatment
Only a decade ago, many in oncology considered chimeric antigen receptor T-cell therapy too fringe for real-world use.